Abivax shares gain as much as 7.4% on Betaville mention

Abivax shares gain as much as 7.4% on Betaville mention

Abivax shares (NASDAQ: ABVX) experienced a significant surge on September 2, 2025, gaining as much as 7.4% during intraday trading. The stock reached a new 52-week high of $81.36, closing at $79.43, with over 1.25 million shares exchanged. This move came after a mention of the company on the financial news platform Betaville.

Analysts have raised their price targets for Abivax, with recommendations ranging from $71.00 to $112.00, leading to a consensus rating of "Buy" and a target price of $92.33 [1]. Institutional investors, including firms like Octagon Capital Advisors and Citadel Advisors, have increased their shareholdings by 83.5% [1].

Key catalysts for Abivax's recent performance include positive Phase 3 trial results for its lead drug candidate, obefazimod, which demonstrated impressive results in treating moderately to severely active ulcerative colitis [2]. The company's ability to pivot its lead candidate from a potential HIV treatment to a successful ulcerative colitis therapy underscores its strategic agility and scientific prowess [2].

The turnaround for Abivax began in July when late-stage data for obefazimod were released, leading to a substantial increase in the company's stock price. The Phase 3 study showed obefazimod to be both safe and effective for patients with moderately to severely active ulcerative colitis [2]. This positive outcome led to a 580% surge in the company's stock price, providing a much-needed boost to biotech hedge funds [2].

Investors and financial professionals should closely monitor Abivax's ongoing development and the potential impact of its success on the broader biotech sector. The company's ability to pivot its lead candidate from a potential HIV treatment to a successful ulcerative colitis therapy underscores its strategic agility and scientific prowess.

References:
[1] https://www.marketbeat.com/instant-alerts/abivax-nasdaqabvx-sets-new-52-week-high-time-to-buy-2025-08-28/
[2] https://www.ainvest.com/news/abivax-580-surge-boosts-biotech-hedge-funds-rare-2025-win-2509/